{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:16:48Z","timestamp":1790083008914,"version":"4.0.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1053\/j.ajkd.2019.03.433","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T08:23:01Z","timestamp":1562833381000},"page":"529-537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Kidney Complications of Immune Checkpoint Inhibitors: A Review"],"prefix":"10.1053","volume":"74","author":[{"given":"Roman","family":"Shingarev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya G.","family":"Glezerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1053\/j.ajkd.2019.03.433_bib1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.1983.1.3.208","article-title":"Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine","volume":"1","author":"Abelson","year":"1983","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1053\/j.ajkd.2019.03.433_bib2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1053\/ajkd.2003.50037","article-title":"Drug-induced Fanconi's syndrome","volume":"41","author":"Izzedine","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2019.03.433_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1053\/j.ajkd.2019.03.433_bib4","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1200\/JCO.1988.6.11.1728","article-title":"Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer","volume":"6","author":"Hansen","year":"1988","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1053\/j.ajkd.2019.03.433_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/sj.bmt.1705573","article-title":"Chronic kidney disease in long-term survivors of hematopoietic cell transplant","volume":"39","author":"Hingorani","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"5425","key":"10.1053\/j.ajkd.2019.03.433_bib6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.285.5425.221","article-title":"The immunological synapse: a molecular machine controlling T cell activation","volume":"285","author":"Grakoui","year":"1999","journal-title":"Science"},{"issue":"3","key":"10.1053\/j.ajkd.2019.03.433_bib7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0952-7915(00)00083-2","article-title":"Signal transduction by the TCR for antigen","volume":"12","author":"Kane","year":"2000","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1053\/j.ajkd.2019.03.433_bib8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-065X.2011.01011.x","article-title":"Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28\/ B7 family","volume":"241","author":"Bour-Jordan","year":"2011","journal-title":"Immunol Rev"},{"issue":"17","key":"10.1053\/j.ajkd.2019.03.433_bib9","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1053\/j.ajkd.2019.03.433_bib10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1053\/j.ajkd.2019.03.433_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2017.08.032","article-title":"Patient-reported outcomes\u00a0in KEYNOTE-006, a randomised study of pembrolizumab\u00a0versus ipilimumab in patients with advanced melanoma","volume":"86","author":"Petrella","year":"2017","journal-title":"Eur J Cancer"},{"issue":"25","key":"10.1053\/j.ajkd.2019.03.433_bib12","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMc1714339","article-title":"Nivolumab and ipilimumab in\u00a0advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2019.03.433_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1053\/j.ajkd.2019.03.433_bib14","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10030","key":"10.1053\/j.ajkd.2019.03.433_bib15","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2\u00a0randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"19","key":"10.1053\/j.ajkd.2019.03.433_bib16","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2019.03.433_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1074-7613(00)00027-3","article-title":"Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis","volume":"13","author":"Bolland","year":"2000","journal-title":"Immunity"},{"issue":"2","key":"10.1053\/j.ajkd.2019.03.433_bib18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"issue":"2","key":"10.1053\/j.ajkd.2019.03.433_bib19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/eji.200939781","article-title":"Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus","volume":"40","author":"Jury","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1053\/j.ajkd.2019.03.433_bib20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s13075-015-0859-z","article-title":"Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways","volume":"17","author":"Liu","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1053\/j.ajkd.2019.03.433_bib21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1084\/jem.185.3.393","article-title":"CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics","volume":"185","author":"van der Merwe","year":"1997","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"10.1053\/j.ajkd.2019.03.433_bib22","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.30176","article-title":"Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1053\/j.ajkd.2019.03.433_bib23","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1365-2796.2009.02096.x","article-title":"Review of recent genome-wide association scans in lupus","volume":"265","author":"Graham","year":"2009","journal-title":"J\u00a0Intern Med"},{"issue":"4","key":"10.1053\/j.ajkd.2019.03.433_bib24","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/ng1020","article-title":"A\u00a0regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans","volume":"32","author":"Prokunina","year":"2002","journal-title":"Nat Genet"},{"issue":"6","key":"10.1053\/j.ajkd.2019.03.433_bib25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/ng2046","article-title":"FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity","volume":"39","author":"Fanciulli","year":"2007","journal-title":"Nat Genet"},{"issue":"2","key":"10.1053\/j.ajkd.2019.03.433_bib26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1053\/j.ajkd.2019.03.433_bib27","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1053\/j.ajkd.2019.03.433_bib28","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2019.03.433_bib29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1053\/j.ajkd.2019.03.433_bib30","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1053\/j.ajkd.2019.03.433_bib31","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"issue":"15","key":"10.1053\/j.ajkd.2019.03.433_bib32","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2019.03.433_bib33","first-page":"11","article-title":"Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma","volume":"10","author":"Berman","year":"2010","journal-title":"Cancer Immun"},{"issue":"34","key":"10.1053\/j.ajkd.2019.03.433_bib34","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 Study","volume":"35","author":"Hammers","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1053\/j.ajkd.2019.03.433_bib35","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2019.03.433_bib36","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1053\/j.ajkd.2019.03.433_bib38","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/cc11454","article-title":"Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1)","volume":"17","author":"Kellum","year":"2013","journal-title":"Crit Care"},{"issue":"11","key":"10.1053\/j.ajkd.2019.03.433_bib39","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1681\/ASN.2004090740","article-title":"Acute kidney injury, mortality, length of stay, and costs in hospitalized patients","volume":"16","author":"Chertow","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2019.03.433_bib40","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/ki.2010.259","article-title":"The duration of postoperative acute kidney injury is an additional parameter predicting long-term survival in diabetic veterans","volume":"78","author":"Coca","year":"2010","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2019.03.433_bib41","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archinte.168.6.609","article-title":"Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction","volume":"168","author":"Newsome","year":"2008","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1053\/j.ajkd.2019.03.433_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"PloS One"},{"issue":"4","key":"10.1053\/j.ajkd.2019.03.433_bib43","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11523-016-0426-9","article-title":"Severe hyponatremia and immune nephritis following an initial infusion of nivolumab","volume":"11","author":"Vandiver","year":"2016","journal-title":"Targeted Oncol"},{"issue":"2","key":"10.1053\/j.ajkd.2019.03.433_bib44","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2019.03.433_bib45","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2019.03.433_bib46","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2019.03.433_bib47","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10637-014-0092-7","article-title":"Kidney injuries related to ipilimumab","volume":"32","author":"Izzedine","year":"2014","journal-title":"Investig New Drugs"},{"issue":"3","key":"10.1053\/j.ajkd.2019.03.433_bib48","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ckj\/sfw024","article-title":"Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Murakami","year":"2016","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1053\/j.ajkd.2019.03.433_bib49","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","article-title":"Nephrotic syndrome with cancer immunotherapies: a report of 2 cases","volume":"70","author":"Kitchlu","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2019.03.433_bib50","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.kint.2015.11.028","article-title":"Ipilimumab-associated minimal-change disease","volume":"89","author":"Kidd","year":"2016","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ajkd.2019.03.433_bib51","first-page":"345","article-title":"Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: a case report","volume":"40","author":"Daanen","year":"2017","journal-title":"J\u00a0Immunother"},{"key":"10.1053\/j.ajkd.2019.03.433_bib52","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.lungcan.2018.05.015","article-title":"Goodpasture's disease in a patient with advanced lung cancer treated with nivolumab: an autopsy case report","volume":"122","author":"Takahashi","year":"2018","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1053\/j.ajkd.2019.03.433_bib53","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12882-016-0408-2","article-title":"Nivolumab-associated acute glomerulonephritis: a case report and literature review","volume":"17","author":"Jung","year":"2016","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2019.03.433_bib54","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"10.1053\/j.ajkd.2019.03.433_bib55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2019.03.433_bib56","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00130832-200208000-00003","article-title":"Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept","volume":"2","author":"Pichler","year":"2002","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"10","key":"10.1053\/j.ajkd.2019.03.433_bib57","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1681\/ASN.2006050418","article-title":"Involvement of drug-specific T cells in acute drug-induced interstitial nephritis","volume":"17","author":"Spanou","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2019.03.433_bib58","first-page":"936","article-title":"Renal effects of immune checkpoint inhibitors","volume":"32","author":"Izzedine","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2019.03.433_bib59","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1615\/CritRevImmunol.v24.i4.10","article-title":"Negative regulation of T-cell\u00a0function by PD-1","volume":"24","author":"Zha","year":"2004","journal-title":"Crit Rev Immunol"},{"issue":"17","key":"10.1053\/j.ajkd.2019.03.433_bib60","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"28","key":"10.1053\/j.ajkd.2019.03.433_bib61","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1053\/j.ajkd.2019.03.433_bib62","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1053\/j.ajkd.2019.03.433_bib63","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/apt.12749","article-title":"Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease","volume":"39","author":"Stidham","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1053\/j.ajkd.2019.03.433_bib64","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1053\/j.ajkd.2019.03.433_bib65","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/CMR.0b013e32835fb524","article-title":"Ipilimumab-induced acute severe colitis treated by infliximab","volume":"23","author":"Pages","year":"2013","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1053\/j.ajkd.2019.03.433_bib66","first-page":"3","article-title":"Drug-induced acute interstitial nephritis: pathology, pathogenesis, and treatment","volume":"9","author":"Krishnan","year":"2015","journal-title":"Iran J Kidney Dis"},{"issue":"19","key":"10.1053\/j.ajkd.2019.03.433_bib67","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2019.03.433_bib68","first-page":"1","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"10.1053\/j.ajkd.2019.03.433_bib69","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CCO.0000000000000505","article-title":"Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?","volume":"31","author":"De Bruyn","year":"2019","journal-title":"Curr Opin Oncol"},{"issue":"34","key":"10.1053\/j.ajkd.2019.03.433_bib70","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2019.03.433_bib71","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of\u00a0anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638619307668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638619307668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:20:48Z","timestamp":1759461648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638619307668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0272638619307668"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2019.03.433","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney Complications of Immune Checkpoint Inhibitors: A Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2019.03.433","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}